Brief: Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
13/05/2024 14:22
May 13 (Reuters) - Sumitomo Pharma Co Ltd 4506.T :
* SUMITOMO PHARMA ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL
NEW
DRUG APPLICATION FOR VIBEGRON IN MEN WITH OVERACTIVE BLADDER
SYMPTOMS RECEIVING PHARMACOLOGICAL THERAPY FOR BENIGN PROSTATIC
HYPERPLASIA
* SUMITOMO PHARMA AMERICA: FDA HAS SET A TARGET ACTION DATE
IN Q3
OF FY2024, UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA)
Source text for Eikon: ID:nPn62ljW4a
Further company coverage: 4506.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)